A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone
Drug Development Research · 2026
DOI: 10.1002/ddr.70350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von İrem Şimşek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Metallochaperones, Zinc, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Mutations in, or misregulation of, Tp53 are found in approximately 50% of all cancers. p53 functions by ensuring that cells with irretrievably damaged DNA undergo apoptosis. Tp53 mutations often induce conformational changes that inhibit activity; however, small‐molecule chaperones could theoretically restore conformation and activity. COTI‐2, a thiosemicarbazone with orphan‐drug status for ovarian cancer, has proven an effective cytotoxic agent against various cancer cell lines in vitro , exhibited efficacy in vivo , and has demonstrated a good safety profile in Phase 1b human clinical trials. The proposed mechanism, direct engagement and refolding of mutant p53, has been supported by a combination of cell‐based assays and transcriptomics data. Through a combination of experimental and computational approaches, we demonstrate that this is an unlikely mechanism of action, and that COTI ‐2 instead likely acts as a selective, well‐tolerated, zinc chaperone to replace zinc ions lost to p53 mutants' deficient zinc‐binding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario, Canada.
- Binary Star Research Services, LaSalle, Ontario, Canada.
- Department of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
- Amaro Therapeutics, New York, New York, USA.
- WE-Spark Research Institute, Windsor, Ontario, Canada.
ORCID-Profile: Samra Khan, John F Trant
Förderung
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Şimşek, İ., Shahbazi-Raz, F., Krause, M. J., Mohammadzadeh, A., Kosar, M., Xu, P., Khan, S., Tykhoniuk, O., DaDalt, A., Almasri, D., Watanabe, L. K., Breault, K., Hayward, J. J., Pick, F. S., Ho, R. L., Rawson, J. M., & Trant, J. F. (2026). A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone. Drug Development Research. https://doi.org/10.1002/ddr.70350
Vancouver
Şimşek İ, Shahbazi-Raz F, Krause MJ, Mohammadzadeh A, Kosar M, Xu P, et al. A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone. Drug Development Research. 2026. doi:10.1002/ddr.70350
BibTeX
@article{imek2026,
author = {Şimşek, İrem and Shahbazi-Raz, Farsheed and Krause, Michael J and Mohammadzadeh, Azam and Kosar, Maryam and Xu, Peihan and Khan, Samra and Tykhoniuk, Olena and DaDalt, Ashley and Almasri, Deya'a and Watanabe, Lara K and Breault, Kaitlyn and Hayward, John J and Pick, Fraser S and Ho, Richard L and Rawson, Jeremy M and Trant, John F},
title = {A Tale of Two Mechanisms: The p53 Modulator COTI‐2 Is a Zn Metallochaperone},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70350}
}
EUVIMED